The intranasal route has gained increased popularity in the pharmaceutical industry in recent years, particularly because of the number of new peptide therapeutic agents. This has led to a corresponding increase in both interest in and performance of toxicity (or as they are called in the pharmaceutical industry, safety assessment) studies by this route. This report reviews the considerations specific to the intranasal route: formulations, devices for administration, special safety concerns, and animal models employed.
Gardner DE, Kennedy GL. Methodologies and technology for animal inhalation toxicology studies. In: Gardner DE, Crapo JD, McClellan RO, eds. Toxicology of the lung. New York: Raven Press, 1993:6–8.
Gad SC, Chengelis CP, Gad SC, Chengelis CP, eds. Animal models in toxicology. New York: Marcel Dekker, 1992:229,698,59.
6.
Huang CH, Kimcera R, Nassar RB, Hussain A. Mechanisms of nasal absorption of drugs. 1. Physiochemical parameters influencing the rate of in situ nasal absorption of drugs in rats. J Pharm Sci1985;74:608–11.
7.
Hussain A, Hirai S, Bawarshi R. Nasal absorption of propranolol from different dosage forms by rats and dogs. J Pharm Sci1989;69:1411–3.
8.
McMartin C, Hutchinson LEF, Hyde R, Peters GE. Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity. J Pharm Sci1987;76:535–40.
9.
Pardridge WM. Peptide drug delivery to the brain. New York: Raven Press, 1991:99–122.
